You are here

American Journal of Cancer Prevention

ISSN (Print): 2328-7322

ISSN (Online): 2328-7314

Editor-in-Chief: Nabil Abdel-Hamid

Website: http://www.sciepub.com/journal/AJCP

   

Article

Role of TACE in Patients with Hepatocellular Carcinoma before Liver Transplantation

1Department of General Surgery, The Thirteenth People's Hospital of Chongqing, Chongqing 400010, China

2Department of Hepatobiliary Surgery, Suining Central Hospital, Suining 629000, China


American Journal of Cancer Prevention. 2016, 4(2), 23-25
doi: 10.12691/ajcp-4-2-1
Copyright © 2016 Science and Education Publishing

Cite this paper:
Cheng Luo, Yakun Wu, Shaoyong Liang. Role of TACE in Patients with Hepatocellular Carcinoma before Liver Transplantation. American Journal of Cancer Prevention. 2016; 4(2):23-25. doi: 10.12691/ajcp-4-2-1.

Correspondence to: Shaoyong  Liang, Department of General Surgery, The Thirteenth People's Hospital of Chongqing, Chongqing 400010, China. Email: 353827514@qq.com

Abstract

Transarterial chemoembolization (TACE) can prevent tumor progression in patients with hepatocellular carcinoma awaiting liver transplantation. This article introduces the effect of TACE before liver transplantation in terms of dropout rate, improvement in overall survival, prediction of survival, and its application as down-stage therapy.

Keywords

References

[1]  Blackburn H, West S. Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer. Cancer Nurs. 2015 Oct 19. [Epub ahead of print].
 
[2]  Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I,et al. “Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation”. World J Gastroenterol 19(34): 5622-5632, Sep 2013.
 
[3]  Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G,et al. “Priority of Candidates With Hepatocellular Carcinoma Awaiting Liver Transplantation Can Be Reduced After Successful Bridge Therapy”, Liver Transpl 17(11):1344-1354, Nov 2011.
 
[4]  Fisher RA, Cotterell AH, Maluf DG, Stravitz RT, Ashworth A, Nakatsuka M, et al. “Adult living donor versus deceased donor liver transplantation:A 10-year prospective single center experience”, Annal of Hepatology 8(4):298-307. Oct 2009.
 
[5]  Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, et al. “Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma”.Clin Transplant, 26(4):359-364, Jul 2012.
 
Show More References
[6]  Fujiki M, Aucejo F, Kim R. “General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option? Liver Int 31(8): 1081-1089, Sep 2011.
 
[7]  Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. “Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation”. World J Gastroenterol 19(43): 7515-7530 Nov 2013.
 
[8]  Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, et al. “Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma”. Liver Transpl 13(2):272-9, Feb 2007.
 
[9]  Decaens T, Roudot-Thoraval F, Bresson-Hadni S, MeyerC, Gugenheim J, Durand F, et al. “Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma”. Liver Transpl 11(7): 767-775, Jul 2005.
 
[10]  Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S, et al. “Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival”. J Am Coll Surg 203(4): 411-420, Oct 2006.
 
[11]  Cescon M, Cucchetti A, Ravaioli M, Pinna AD. “Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplant ability and recurrence rate”. J Hepatol 58(3): 609-618, Mar 2013.
 
[12]  Tsochatzis E, Garcovich M, Marelli L, Papastergiou V, Fatourou E, Rodriguez Peralvarez ML et al. “Transarterial chemoembolization as neo-adjuvant therapy pre-transplantation in patients with hepatocellular carcinoma”. Liver Int. 33(6):944-949, Jul 2013.
 
[13]  Eswaran SL, Pierce K, Weaver F, Rogers T, Brems JJ, Sontag SJ, et al. “Transarterial Chemoembolization for HCC in Patients With Extensive Liver Transplantation Waiting Times”. Angiology 63(3):206-12, Apr 2012.
 
[14]  Vivanco M, Gabrielli M, Jarufe N, Humeres R, Rios H, Palacios JM, et al. “Bridge therapy in hepatocellular carcinoma before liver transplantation: the experience of two Chilean centers”. Transplant Proc 42(1):296-304 Jan 2010.
 
[15]  Cotoi CG, Khorsandi SE, Pleşea IE, Quaglia A. “Histological aspects of post-TACE hepatocellular carcinoma”. Rom J Morphol Embryol 53(3): 677-682, 2012.
 
[16]  Otto G, Schuchmann M, Hoppe-Lotichius M, Heise M, Weinmann A, Hansen T. “How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions rresponse to TACE?” J Hepatol 59(2): 279-284. Aug 2013.
 
[17]  Chan KM, Yu MC, Chou HS, Wu TJ, Lee CF, Lee WC. “Significance of Tumor Necrosis for Outcome of Patients with Hepatocellular Carcinoma Receiving Locoregional Therapy Prior to Liver Transplantation”. Ann Surg Oncol 18(9): 2416-2426. Sep 2011.
 
[18]  Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, et al. “Hepatocellular Carcinoma: CT for Tumor Response after Transarterial Chemoembolization in Patients Exceeding Milan Criteria—Selection Parameter for Liver Transplantation”. Radiology. 255(1):289-300, Apr 2010.
 
[19]  Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L, Pomier-Layrargues G. “Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma as a Bridge to Liver Transplantation: A Retrospective Study”. Int J Hepatol. 974514, Jan 2011.
 
[20]  Schaudt A, Kriener S, Schwarz W, Wullstein C, Zangos S, Vogl T, et al. “Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis”. Clin Transplant 23(21): 61-67, Dec 2009.
 
[21]  Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D. “Is the Treatment of Hepatocellular Carcinoma on the Waiting List Necessary?” Liver Transpl 17:S98-108, Oct 2011.
 
[22]  Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA. “Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria”. Br J Surg 98(9): 1201-1208, Sep 2011.
 
[23]  Chapman WC , Majella Doyle MB , Stuart JE , Vachharajani N , Crippin JS , Anderson CD, et al. “Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation”. Annals of surgery 248(4):617-642, Oct 2008.
 
Show Less References

Article

Sexual Behavioral Pattern, Cervical Cancer Awareness and Screening Practices among Female Undergraduate Students of Public Universities in Anambra State, Nigeria

1Department of Community Medicine, Chukwuemeka Odumegwu Ojukwu University Awka, Nigeria

2Department of HIV Care and Department of Community Medicine, Nnamdi Azikiwe University Teaching Hospital Nnewi, Nigeria

3Department of Community Medicine, Chukwuemeka Odumegwu Ojukwu University / University Teaching Hospital Awka, Nigeria

4Department of Obstetrics and Gynecology, Nnamdi Azikiwe University Teaching Hospital Nnewi, Nigeria

5Department of Community Medicine, Nnamdi Azikiwe University/University Teaching Hospital Nnewi, Nigeria

6Department of Obstetrics and Gynecology, Nnamdi Azikiwe University/University Teaching Hospital Nnewi, Nigeria


American Journal of Cancer Prevention. 2016, 4(2), 26-32
doi: 10.12691/ajcp-4-2-2
Copyright © 2016 Science and Education Publishing

Cite this paper:
Valentine C Ilika, Chinomnso C Nnebue, Ngozi N Ikechebelu, Chito P Anyanwu, Amobi L Ilika, Joseph I Ikechebelu. Sexual Behavioral Pattern, Cervical Cancer Awareness and Screening Practices among Female Undergraduate Students of Public Universities in Anambra State, Nigeria. American Journal of Cancer Prevention. 2016; 4(2):26-32. doi: 10.12691/ajcp-4-2-2.

Correspondence to: Chinomnso  C Nnebue, Department of HIV Care and Department of Community Medicine, Nnamdi Azikiwe University Teaching Hospital Nnewi, Nigeria. Email: nnebnons@yahoo.com

Abstract

Background: Risky sexual behavior, low level of awareness and poor screening uptake have been linked to the high prevalence of cervical cancer in our environment. Objective: To determine the sexual behavioral pattern, cervical cancer awareness and screening practices among female undergraduate students of public universities in Anambra state, Nigeria. Materials and methods: This was a descriptive cross sectional study of 342 female undergraduate students in Anambra state, Nigeria selected using a two stage sampling. Data was collected using a pre-tested semi-structured questionnaire and analysed using statistical package for social sciences version 22.0. Chi-square test was used to identify statistically significant associations between variables. A p value of ≤ 0.05 was considered significant. Results: The modal age at menarche, 215 (62.9%) was 13-15 years, while 18 (5.3%) first menstruated at ages below 10 years. Of the 311 (71.6%) that ever had sex, 289 (92.9%) had their coitarche at ages below 24 years, 209 (67.2%) were sexually active while 48 (15.4%) had multiple sex partners. About 310 (90.6%) have heard of cervical cancer, 269 (78.8%) were aware of cervical cancer screening, out of which 108 (40.2%) were aware of cervical cancer screening tests with Pap smear as the most mentioned screening test by 55 (51.0%). There were statistically significant associations between uptake of cervical cancer screening and [ever been pregnant (p=0.005), ever used contraceptives (p=0.001) and perceived need for cervical cancer screening (p=0.000) respectively. Conclusions: This study showed a good level of awareness of cervical cancer but cervical cancer screening practices was inadequate. We recommend educational programs and comprehensive cervical cancer screening strategy.

Keywords

References

[1]  Adefuye PO. Knowledge and practice of cervical screening among professional health workers in a suburban district in Nigeria. Nigerian Medical Practitioner.2006;50:19-22.
 
[2]  Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al., Estimated cancer incidence, mortality and prevalence worldwide in 2012. GLOBOCAN. 2012.Available@http://globocan.iarc.fr/Pages/fact_sheets_population.aspx,v1.0, [Accessed on 22 May, 2016].
 
[3]  Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al., Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet.2011;378 (9801):1461-84.
 
[4]  Africa Health, Human and Social Development Information Service (Afri--‐Dev. Info i.e. Formerly Africa Public Health .Info), Africa Coalition on Maternal Newborn and Child Health. Summary scorecard and research findings at end of scorecard including: Global/Africa Continental/Sub Regional and Country trends; and links with Sexual and Reproductive Health (SRH), HIV/AIDS, Adolescent and Maternal Health. Advancing multi-sectoral policy and investment for girls, women and children’s health. 2014. [Accessed on 22 May, 2016].
 
[5]  Jedy-Agba E, Curado MP, Ogunbiyi O, Oga E, Fabowale T, Igbinoba F, et al., Cancer incidence in Nigeria: a report from population-based cancer registries. Cancer Epidemiol. 2012; 36(5): e271-8.
 
Show More References
[6]  Bayo S, Bosch FX, de Sanjose S, Munoz N, Combita AL Coursage P, et al. Risk factors of invasive cervical cancer in Mali. International Journal of Epidemiology 2002; 31:202-9.
 
[7]  Muñoz N, Fransceschi S, Bossetti C, Moreno V, Herrero R Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: The IARC Multicentric Case-Control Study. Lancet 2002;359:1093-101.
 
[8]  World Health Organization (WHO). Comprehensive cervical cancer control: A guide to essential practice. Screening for cervical cancer. Geneva, WHO Press.2002.
 
[9]  Adjorlolo-Johnson G, Unger ER, Boni-Ouattara E, Coulibaly KT, Maurice C, Vernon SD, et al.,. Assessing the relationship between HIV infection and cervical cancer in Côte d’Ivoire: A case–control study. BMC Infect. Dis. 2012;10:242.
 
[10]  Mbamara SU, Ikpeze OC, Okonkwo JE, Onyiaorah IV, Ukah CO. Knowledge, attitude and practice of cervical cancer screening among women attending gynecology clinics in a tertiary level medical care center in southeastern Nigeria. J Reprod Med. 2011;56(11-12):491-6.
 
[11]  Program for Appropriate Technology in Health. Planning appropriate cervical cancer prevention programs, 2nd edition. Seattle, 2000.
 
[12]  Sherris J, Castro W, Lewin C, Dzuba I, Arossi S. The case for investing in cervical cancer prevention. Cervical Cancer Prevention Issues in Depth no. 3. Alliance for Cervical Cancer Prevention. 2004, Seattle. Available@ www.path.org/files/ RH_accp _case.pdf. [Accessed on 22 May, 2016].
 
[13]  Nnebue CC. The Epidemiological transition: policy and planning implications for developing countries. Niger J Med. 2010; 19(3): 250-6.
 
[14]  World Health Organization. Human papillomavirus and cervical Cancer. 2010. Available@http://www.who.int/mediacentre/factsheets/fs380/en/.[Accessed on 22 May, 2016].
 
[15]  Naseema BA, Smitha SK. Awareness of cervical cancer and Pap smear and it’s utilization among health care workers in medical college, Kozhikode. Journal of Evidence Based Medicine and Healthcare.2014;1(2):48-53.
 
[16]  Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev.2013;2:35.
 
[17]  Dang J, Lee J, Tran JH. Knowledge, attitudes, and beliefs regarding breast and cervical cancer screening among Cambodian, Laotian, Thai, and Tongan Women. J Cancer Educ.2010: 25: 595-601.
 
[18]  World Health Organization. Comprehensive cervical cancer control: A guide to essential practice. Geneva, Switzerland. 2005a.p.272.
 
[19]  World Health Organization (WHO). WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva, Switzerland: WHO.2013.
 
[20]  Pan American Health Organization. Situational analysis of cervical cancer prevention and control in the Caribbean: results from a 2013 assessment of country policies and services for HPV vaccination, cervical cancer screening, diagnosis and treatment. 2013.
 
[21]  Botha H, Cooreman B, Dreyer G, Lindeque G, Mouton A, Guidozzi F, et al. Cervical cancer and human papillomavirus: South African guidelines for screening and testing. South Afr J Gynaecol Oncol.2010; 2:23-26.
 
[22]  The United States Preventive Services Task Force (USPSTF). Screening for cervical cancer: clinical summary of USPSTF recommendation. AHRQ Publication No. 11-05156-EF-3, March 2012. Available@:http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/ cervcancersum.htm. [Accessed on 22 May, 2016].
 
[23]  American Cancer Society. Screening guidelines for the prevention and early detection of cervical cancer. American Cancer Society, Atlanta, Ga.2012. Available@ http://www.cancer.org. [Accessed on 22 May, 2016].
 
[24]  Pengpid S, Peltzer K. Attitudes and practice of cervical cancer screening among female university students from 25 low, middle income and emerging economy countries Asian Pacific Journal of Cancer Prevention.2014;15:7235-9.
 
[25]  Akujobi CN, Ikechebelu JI, Onunkwo I, Onyiaorah IV. Knowledge, attitude and practice of screening for cervical cancer among female students of a tertiary institution in South Eastern Nigeria. Niger J Clin Pract.2008;11:216-9.
 
[26]  Aniebue PN, Aniebue UU. Awareness and practice of cervical cancer screening among female undergraduate students in a Nigerian university. J Cancer Educ.2010;25: 106-8.
 
[27]  Ayinde OA, Omigbodun AO, Ilesanmi AO. Awareness of cervical cancer, papanicolaou’s smear and its utilisation among female undergraduates in Ibadan. Afr J Reprod Hlth,2004;8:68-80.
 
[28]  Oladepo O, Ricketts OL, John-Akinola Y. Knowledge and utilization of cervical cancer screening services among Nigerian students. Int Q Community Health Educ.2008/9;29:293-304.
 
[29]  Abotchie PN, Shokar NK. Cervical cancer screening among college students in Ghana: knowledge and health beliefs. Int J Gynecol Cancer.2009;19:412-6.
 
[30]  Dhendup T, Tshering P. Cervical cancer knowledge and screening behaviors among female university graduates of year 2012 attending national graduate orientation program, Bhutan. BMC Womens Health.2014;14:44.
 
[31]  Bakogianni GD, Goutsou SC, Liti MV, Rizopoulou SI, Nikolakopoulos KM, Nikolakopoulou NM. Knowledge, attitude, and practice of cervical cancer screening among Greek students: a short report. Int J Adolesc Med Health.2012;24:329-30.
 
[32]  Durvasula 7238 Durvasula RS, Regan PC, Ureño O, Howell L (2006). Frequency of cervical and breast cancer screening rates in a multi-ethnic female college sample. Psychol Rep.2006;99:418-20.
 
[33]  Hyacinth HI, Adekeye OA, Ibeh JN, Osoba T. Cervical cancer and Pap smear awareness and utilization of pap smear test among Federal civil servants in North Central Nigeria. PLoS One.2012;7(10):e46583.
 
[34]  Araoye MO. Research methodology with statistics for health and social sciences. Nathadex Publications, saw-mill, Ilorin 2nd ed.2008:p 115- 22.
 
[35]  Statistical Package for Social Sciences (IBM SPSS) 22.0 version. Armonk NY: IBM United States. IBM Corp. 2013.
 
[36]  Kishore J, Mundra V, Grewal I. Perception and use of Pap smear among medical personnel in New Delhi, India. Health and Population: Perspectives and Issues.2009;32:141-147
 
[37]  Ezem B U. Awareness and uptake of cervical cancer screening in Owerri, South-Eastern Nigeria. Ann Afr Med.2007;6:94-8.
 
[38]  Bukar M Takai IU , Audu BM .Determinants of utilization of papanicolaou smear among outpatient clinic attendees in north-eastern Nigeria. African Journal of Medicine and Medical Sciences.2012;41(2):183-9
 
[39]  Onajole AT, Ajekigbe AT, Bamgbala AO, Odeyemi KA, Ogunnowo BO, Osisanya TF, et al. The socio-demographic characteristics and level of awareness of prevention of cancer of the cervix among commercial sex workers in Lagos, Nigeria. Nigerian Medical Practitioner.2004;45:52-5.
 
[40]  Duru CB, Abejegah C, Nnebue CC, Uwakwe KA, Obi- Okaro AC, Azuogu BC. Heterosexual behaviour, awareness and practice of cervical cancer screening among female staff and students in a private tertiary institution in South-south, Nigeria. Indian Journal of Medical Research and Pharmaceutical Sciences. 2014;1(6):1-9.
 
[41]  Obiechina NJ, Mbamara SU. Knowledge attitude and practice of cervical cancer screening among sexually active women in Onitsha, southeast Nigeria. Niger J Med. 2009;18(4):384-7.
 
Show Less References

Article

A Case of Second Primary Multiple Myeloma Mimicking Bone Metastases in a Patient with Breast Cancer: An Approach to Osseous Metastases

1Department of Medical Oncology, Yuzuncu Yil University Medical Faculty, Van, Turkey


American Journal of Cancer Prevention. 2016, 4(2), 33-35
doi: 10.12691/ajcp-4-2-3
Copyright © 2016 Science and Education Publishing

Cite this paper:
Nurhan Onal Kalkan, Muhammed Aslanboga, Erkan Dogan. A Case of Second Primary Multiple Myeloma Mimicking Bone Metastases in a Patient with Breast Cancer: An Approach to Osseous Metastases. American Journal of Cancer Prevention. 2016; 4(2):33-35. doi: 10.12691/ajcp-4-2-3.

Correspondence to: Erkan  Dogan, Department of Medical Oncology, Yuzuncu Yil University Medical Faculty, Van, Turkey. Email: drerkandogan1@gmail.com

Abstract

A 62-year-old female patient received adjuvant chemotherapy after a mastectomy due to a locally advanced invasive ductal carcinoma eight years ago. During the follow-up, she complained of extensive backache, so a plain radiography was taken. The radiography showed diffuse lytic lesions located primarily around the vertebrae and sternum. Given that the bone lesions could be related to osseous metastases of the breast cancer, a bone scintigraphy was performed and no positive involvement was observed. Magnetic resonance imaging was subsequently applied and diffuse hypointense areas were found on the vertebrae. The patient had also accompanying bicytopenia (thrombocytopenia and luecocytopenia), albumin/globulin inversion and hyperglobulinemia. As the patient did not have such involvement in regard to her overall body scintigraphy and there were accompanying abnormal biochemical parameters, it was concluded that the patient’s bone lesions were an outcome of a hematological malignity. Bone marrow aspiration and the biopsy result were found to be consistent with multiple myeloma (MM). It was thus confirmed that the lytic lesions were not related to breast cancer but rather MM bone lesions. We are able to conclude, based on the case presented herein, that newly-developing bone lesions on patients with breast cancer must be approached with suspicion, and their other laboratory analyses and imaging diagnostic processes must be evaluated carefully. It is necessary to keep in mind that such a condition might be related to other diseases, however rare the occurrence.

Keywords

References

[1]  Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
 
[2]  Sinn HP, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care (Basel) 2013;8:149-154.
 
[3]  Puglisi F, Follador A, Minisini AM et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:236-6.
 
[4]  Yochum TR, Rowe LJ. Tumors and Tumorlike Processes; Essentials of Skeletal Radiology. Baltimore: Williams & Wilkins, 1996: 1004-13.
 
[5]  Carnesale PG. Malignant Bone Tumors; Campbell’s Operative Orthopaedics. St.Louis: Mosby-Year Book Inc, 1998: 726-727.
 
Show More References
[6]  Clayer M, Duncan W. Importance of biopsy of new bone lesions in patients with previous carcinoma. Clin Orthop Relat Res. 2006;451:208-11.
 
[7]  Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-64. Review.
 
[8]  R. Gunderman, Essential Radiology, Thieme Medical Publishers, New York, NY, USA, 2nd edition, 2006
 
[9]  Hopkins GB, Kristensen KA. Whole body skeletal scintiphotography in the detection of occult metastatic breast carcinomas. Calif Med. 1973;119:10-3.
 
[10]  Galasko CS. Skeletal metastases and mammary cancer. Ann R Coll Surg Engl. 1972;50:3-28.
 
[11]  Dillman CE Jr, Silverstein MN. Alkaline phosphatase in multiple myeloma. Am J Med Sci. 1965;249:445-7.
 
[12]  Fried JR, Goldberg H, Herrman JB. Treatment of metastases from cancer of the breast. Am JRoentgenol 1950; 63:312-33.
 
[13]  Yochum TR, Rowe LJ. Tumors and Tumorlike Processes; Essentials of Skeletal Radiology. Baltimore: Williams & Wilkins, 1996: 1004-13.
 
[14]  Brown SB, Mallon EA, Edwards J et al.TG. Is the biology of breast cancer changing? A study of hormone receptor status 1984-1986 and 1996-1997. Br J Cancer. 2009;100:807-10.
 
Show Less References